ADC THERAPEUTICS SA (ADCT) Forecast, Price Target & Analyst Ratings
NYSE:ADCT • CH0499880968
4.23 USD
+0.12 (+2.92%)
At close: Mar 9, 2026
4.23 USD
0 (0%)
After Hours: 3/9/2026, 8:04:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ADC THERAPEUTICS SA (ADCT).
Forecast Snapshot
Consensus Price Target
$8.16
+ 92.91% Upside
Next Earnings Forecast
Release DateMar 10, 2026
PeriodQ4 / 2025
EPS Estimate-$0.28
Revenue Estimate21.08M
ChartMill Buy Consensus
86.67%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.16
Upside
+ 92.91%
From current price of $4.23 to mean target of $8.16, Based on 12 analyst forecasts
Low
$5.05
Median
$8.16
High
$10.50
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for ADCT. The average price target is 8.16 USD. This implies a price increase of 92.91% is expected in the next year compared to the current price of 4.23.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
ADCT was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about ADCT.
In the previous month the buy percentage consensus was at a similar level.
ADCT was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-20 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-13 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-03-31 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-24 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-01-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-05-30 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-05 | Guggenheim | Reiterate | Buy |
| 2024-03-28 | Guggenheim | Initiate | Buy |
| 2024-03-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-26 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 10, 2026
PeriodQ4 / 2025
EPS Estimate-$0.28
Revenue Estimate21.08M
Revenue Q2Q24.66%
EPS Q2Q4.45%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
4.13%
Revenue (3 Months)
12.75%
EPS (1 Month)
2.98%
EPS (3 Months)
6.32%
Next Earnings Summary
ADCT is expected to report earnings on 3/10/2026. The consensus EPS estimate for the next earnings is -0.28 USD and the consensus revenue estimate is 21.08M USD.
The next earnings revenue estimate has been revised upward by 12.75% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 209.9M 519.17% | 69.558M -66.86% | 70.837M 1.84% | 81.434M 14.96% | 82.295M 1.06% | 153.83M 86.93% | 261.86M 70.23% | 320.18M 22.27% | 376.44M 17.57% | 400.65M 6.43% | |
| EBITDA YoY % growth | -118.57M 55.62% | -164.799M -38.99% | -129.32M 21.53% | -169.32M -30.93% | -162.18M 4.22% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -120.9M 55.19% | -165.986M -37.29% | -130.654M 21.29% | -134.064M -2.61% | -119.586M 10.80% | -71.324M 40.36% | -22.954M 67.82% | 17.879M 177.89% | 61.226M 242.45% | 73.178M 19.52% | |
| Operating Margin | -57.60% | -238.63% | -184.44% | -164.63% | -145.31% | -46.37% | -8.77% | 5.58% | 16.26% | 18.26% | |
| EPS YoY % growth | -2.01 28.21% | -2.93 -45.77% | -1.65 43.69% | -1.42 13.97% | -1.10 22.75% | -0.70 36.37% | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.28 4.45% | -0.27 24.92% | -0.28 27.53% | -0.29 4.80% | -0.30 -8.59% |
| Revenue Q2Q % growth | 21.08M 24.66% | 19.194M -16.67% | 20.604M 9.37% | 20.604M 25.43% | 19.074M -9.52% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -30.68M 5.41% | -23.67M 16.84% | -24.174M 22.16% | -25.194M 17.65% | -27.03M 11.90% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
16.40%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
27.47%
Revenue Next 5 Year
33.94%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ADC THERAPEUTICS SA / ADCT Forecast FAQ
What do analysts expect the price target to be for ADC THERAPEUTICS SA (ADCT)?
12 analysts have analysed ADCT and the average price target is 8.16 USD. This implies a price increase of 92.91% is expected in the next year compared to the current price of 4.23.
Can you provide the upcoming earnings date for ADC THERAPEUTICS SA?
ADC THERAPEUTICS SA (ADCT) will report earnings on 2026-03-10, before the market open.
Can you provide the consensus estimates for ADC THERAPEUTICS SA next earnings?
The consensus EPS estimate for the next earnings of ADC THERAPEUTICS SA (ADCT) is -0.28 USD and the consensus revenue estimate is 21.08M USD.
Can you provide the analyst count for ADC THERAPEUTICS SA stock?
The number of analysts covering ADC THERAPEUTICS SA (ADCT) is 12.